Semaglutide 5mg

Semaglutide's clinical data is genuinely strong, and it comes from some of the largest trials ever run on an obesity/metabolic drug:

• STEP 1 (NEJM, 2021, N=1,961): 68 weeks of weekly 2.4mg semaglutide produced 14.9% average weight loss vs. 2.4% on placebo. 86.4% of participants lost 5% or more of body weight, vs. 31.5% on placebo.
• STEP 5 (2-year extension): average weight loss held at 15.2% vs. 2.6% on placebo at week 104 — the effect isn't a short-term spike.
• SELECT (NEJM, 2023, N=17,604 adults with obesity/overweight and prior cardiovascular disease, no diabetes): semaglutide reduced the composite of cardiovascular death, non-fatal heart attack, or non-fatal stroke by roughly 20% relative to placebo — the first GLP-1 trial of this scale to show a direct cardiovascular benefit, not just weight loss.

The caveat that matters: every one of these results comes from the FDA-approved, pharmacy-dispensed product (Ozempic/Wegovy), manufactured to a validated purity and concentration standard, at doses reached through a supervised titration schedule. None of it transfers automatically to a "research-labeled" vial from an unregulated seller — same molecule name, but no guarantee of the same purity, concentration, or manufacturing standard the trial data was generated on. See Tirzepatide's page for the closest related GLP-1/GIP dual-agonist comparison — cross-trial context, not a head-to-head trial.

The FDA-approved product's real titration schedule (Wegovy, weight-management indication): 0.25mg weekly for weeks 1-4, 0.5mg weeks 5-8, 1mg weeks 9-12, 1.7mg weeks 13-16, then a 2.4mg weekly maintenance dose from week 17 onward — delivered via a pre-filled subcutaneous injection pen. Ozempic (type 2 diabetes indication) follows a shorter titration up to a 2mg weekly maximum.

As of December 22, 2025, the FDA also approved a once-daily oral 25mg tablet (oral Wegovy) for chronic weight management — the first oral GLP-1 approved for this use, based on the OASIS trial program showing 16.6% average weight loss with adherence.

There is no clinically validated dosing protocol for research-labeled semaglutide vials. The titration schedule above is specific to the FDA-approved formulation's validated concentration — it does not carry over to a reconstituted powder of unknown actual concentration from an unregulated source.

The dominant side effects across the trial program are gastrointestinal — nausea, vomiting, and diarrhea — described as mostly transient and mild-to-moderate, concentrated during dose escalation.

The FDA-approved product carries a boxed warning for thyroid C-cell tumors. In animal studies, semaglutide caused dose-dependent thyroid C-cell tumors in rodents; whether this applies to humans has not been determined, and human trial data hasn't shown an increased risk of medullary thyroid carcinoma. It's still contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

This is one of the few compounds on this site where the legal landscape has shifted dramatically and recently, and it's worth knowing about before buying. The FDA removed semaglutide from its official drug shortage list on February 21, 2025 — while it was on that list, compounding pharmacies had a legal basis to make and sell compounded versions during the supply shortfall. Once it came off, that legal cover disappeared.

Novo Nordisk (the manufacturer) has since filed a wave of litigation: 14 lawsuits filed in a single week in August 2025 against compounding pharmacies and telehealth companies selling non-FDA-approved products marketed as "semaglutide." This is an active, ongoing legal fight, not a settled or historical one — worth factoring in as part of the actual risk profile of a research-labeled vial, separate from any purity/dosing concerns.